Deadline
Passed
Lead Plaintiff Deadline: October 23, 2018
(i) CV Sciences’ Patent for CVSI-007, the Company’s leading drug candidate, had been rejected by the USPTO; (ii) accordingly, CV Sciences had significantly overstated the commercial viability of CVSI-007; and (iii) as a result, CV Sciences’ public statements were materially false and misleading at all relevant times.